AL
ALEC.O
—
NASDAQ
Pharmaceuticals & Medical Research
Alector Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
167,6M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-741,3 %
ROE
-466,3 %
Net margin
-679,2 %
Debt / equity
0,32
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$2,19
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Alector Inc is a biotechnology company focused on the discovery and development of therapeutics for neurodegenerative diseases, including Alzheimer's and Parkinson's.
Business. Alector Inc (ALEC.O) is a biotechnology and medical research company listed on the NASDAQ. The firm operates within the pharmaceuticals and medical research sector, focusing on product-based revenue models typical of the industry. As specific operating segments and geographic breakdowns are not provided, the company is described at the industry level. Headquarters location details are not included in the available facts.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
HOLD8 analysts
3 buy3 hold2 sell
Avg 12m price target3,10
Analyst recommendations
8 analysts · consensus HoldBuy3
Hold3
Sell2
12-month price target
3,10
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Hold
8 analysts · indicative
Ownership→
BlackRock Institutional Trust Company, N.A.
largest disclosed fund holder
Profitability→
-466,3 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to ALEC.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Alector Inc (ALEC.O) is a biotechnology and medical research company listed on the NASDAQ. The firm operates within the pharmaceuticals and medical research sector, focusing on product-based revenue models typical of the industry. As specific operating segments and geographic breakdowns are not provided, the company is described at the industry level. Headquarters location details are not included in the available facts.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
AI synthesis
GENERATEDAlector maintains a strong liquidity position with $65.8 million in cash and equivalents, which is 25.8% of total assets, and a current ratio of 3.83, indicating the company can cover its short-term liabilities multiple times over. The company's price-to-book ratio of 8.95 suggests a premium valuation relative to its book value, while the debt-to-equity ratio of 0.32 indicates a conservative capital structure with limited leverage.
Despite a revenue of $21.05 million, Alector reported a net loss of $142.93 million and an operating loss of $156.01 million, reflecting the high R&D costs typical in the biotechnology industry. The return on equity of -4.66% and return on assets of -0.49% underscore the company's unprofitability, which is not uncommon for early-stage biotech firms with no commercial products yet.
Alector's revenue is not segmented by product or geography in the latest financial data, but the company's focus is on neurodegenerative diseases, with clinical-stage programs in Alzheimer's and Parkinson's. The company's geographic exposure is likely concentrated in the United States, as is typical for biotech firms, though no specific geographic breakdown is provided in the available data.
The company's outlook for the current fiscal year is for continued losses, with no indication of near-term revenue growth. The operating cash flow of -$184.03 million and free cash flow of -$137.25 million highlight the ongoing cash burn, which is expected to continue as the company advances its pipeline. Analysts have a mixed outlook, with a mean price target of $3.10 and a median of $2.00, suggesting limited upside potential in the near term.
Alector's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital expenditures are minimal at -$41,000, and there are no significant dilution sources identified in the latest filings. The company's valuation is supported by its pipeline of clinical-stage assets, but the high cash burn and lack of commercial products remain key risks.
Recent events include the continued advancement of its lead programs, including AL001 and AL002, in clinical trials. The company has also engaged in strategic collaborations to support its research and development efforts. No major regulatory or legal events have been reported in the latest filings, and the company's risk assessment remains stable.
Key takeaways
- Alector has a strong liquidity position with $65.8 million in cash and equivalents, but is currently unprofitable with a net loss of $142.93 million.
- The company's valuation is supported by its clinical-stage pipeline, but the high cash burn and lack of commercial products remain key risks.
- Analysts have a mixed outlook, with a mean price target of $3.10 and a median of $2.00, suggesting limited upside potential in the near term.
- Alector's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected.
- The company's focus on neurodegenerative diseases, including Alzheimer's and Parkinson's, positions it in a high-growth but high-risk therapeutic area.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$1,51
Market cap
$274.2M
Enterprise valueⓘ
$218.1M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
8.9x
P / Tangible bookⓘ
8.9x
Tangible book
$30.6M
Net cashⓘ
$56.1M
Current ratioⓘ
3.8
Debt / equityⓘ
0.3
ROAⓘ
-48.7%
ROEⓘ
-4.7%
Cash conversionⓘ
129.0%
CapEx / revenueⓘ
-0.2%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs ALEC · multiples and returns
KL
KLAR—
KLAR.ST
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BN
BNTX—
Biontech SE
$92,25
23,3B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
EX
EXEL—
Exelixis Inc
$55,06
14,7B USDP/E
19,5x
— vs self
Div yield
—
— vs self
ROE
40,4 %
+506,8 vs self
MD
MDGL—
Madrigal Pharmaceuticals Inc
$482,00
11,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-47,8 %
+418,5 vs self
IN
INSM—
Insmed Inc
$107,46
23,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-160,2 %
+306,2 vs self
VC
VCYT—
Veracyte Inc
$45,30
3,6B USDP/E
55,5x
— vs self
Div yield
—
— vs self
ROE
5,1 %
+471,4 vs self
MD
MDXG—
Mimedx Group Inc
$4,27
636,0M USDP/E
11,1x
— vs self
Div yield
—
— vs self
ROE
18,9 %
+485,3 vs self
AV
AVIR—
Atea Pharmaceuticals Inc
$4,61
—P/E
—
— vs self
Div yield
—
— vs self
ROE
-57,5 %
+408,8 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-1,20
Predicted surprise
+0,00
Beat probability
45 %
Analysts
8
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-04 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,20 |
| Revenue | —no estimate | —no estimate | 21,9M USD |
| Operating income | —no estimate | —no estimate | -158,7M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution8 analysts
Strong buy1
Buy2
Hold3
Sell2
Strong sell0
12-month price target$3,10 · Median $2,00
Low $1,00High $6,00
Operating income · consensus-158,7M USD
EPS surprise
−15,4 %
reported vs consensus · miss
Revenue surprise
−3,7 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$1,00
Mean$3,10
Median$2,00
High$6,00
Spot$1,51
+105.3 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-741,3 %Below median
Net Margin-679,2 %Below median
ROE-466,3 %Bottom quartile
Capex / Rev-0,2 %Above P75
D/E0,32Bottom quartile
Cash Conv1,29Above P75
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 66 150 sh7 grants7 insiders
- Director · Stock Option (right to buy) → Common StockAcquired 9 450grant · 2026-06-17
- Director · Stock Option (right to buy) → Common StockAcquired 9 450grant · 2026-06-17
- Director · Stock Option (right to buy) → Common StockAcquired 9 450grant · 2026-06-17
- Director · Stock Option (right to buy) → Common StockAcquired 9 450grant · 2026-06-17
- Director · Stock Option (right to buy) → Common StockAcquired 9 450grant · 2026-06-17
- Director · Stock Option (right to buy) → Common StockAcquired 9 450grant · 2026-06-17
- Director · Stock Option (right to buy) → Common StockAcquired 9 450grant · 2026-06-17
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
Source documents
- Alector Inc Market data — financials · 2026-05-27
- Alector Inc Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2024-06-300,00 %$41M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$11M
- Investment Managers · as of 2026-03-310,00 %$4M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-12-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Funds · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Net selling0 buys · 16 sellsnet -$727K11 insiders · last 365d
- Director · Common StockOther 28 700 · 2026-06-17
- Director · Common StockOther 28 700 · 2026-06-17
- Director · Common StockOther 28 700 · 2026-06-17
- Director · Common StockOther 28 700 · 2026-06-17
- Director · Common StockOther 28 700 · 2026-06-17
- Director · Common StockOther 28 700 · 2026-06-17
- Director · Common StockOther 28 700 · 2026-06-17
- Principal Accounting Officer · Common StockSold 3 475 @ $1,88$7K · 2026-06-03
- Director, Chief Executive Officer · Common StockSold 87 216 @ $1,97$172K · 2026-06-02
- Principal Accounting Officer · Common StockSold 5 709 @ $1,97$11K · 2026-06-02
- CFO & Chief Business Officer · Common StockSold 19 360 @ $1,97$38K · 2026-06-02
- Director · Common StockOther 10 833 · 2026-06-01
- Principal Accounting Officer · Common StockSold 1 820 @ $2,65$5K · 2026-04-16
- CFO & Chief Business Officer · Common StockOther 54 600 · 2026-03-15
- Director, Chief Executive Officer · Common StockOther 116 246 · 2026-03-13
- Principal Accounting Officer · Common StockSold 1 000 @ $2,65$3K · 2026-03-10
- Principal Accounting Officer · Common StockSold 3 367 @ $2,08$7K · 2026-03-03
- Director, Chief Executive Officer · Common StockSold 81 864 @ $2,12$174K · 2026-03-02
- Principal Accounting Officer · Common StockSold 8 071 @ $2,12$17K · 2026-03-02
- CFO & Chief Business Officer · Common StockSold 29 649 @ $2,12$63K · 2026-03-02
- Principal Accounting Officer · Common StockSold 4 079 @ $2,50$10K · 2026-02-26
- Principal Accounting Officer · Common StockSold 4 753 @ $1,21$6K · 2025-12-05
- Director, Chief Executive Officer · Common StockSold 104 347 @ $1,12$117K · 2025-12-03
- Principal Accounting Officer · Common StockSold 8 056 @ $1,12$9K · 2025-12-03
- Chief Bus Ofcr & Interim CFO · Common StockSold 37 261 @ $1,12$42K · 2025-12-03
Short positioning
5.7Mshares short-0.9% vs prior
10.19days to cover
54.2%short of daily vol
2.7Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
ALEC.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data- Total assets (YoY) (2025-12-31 vs 2024-12-31): -37.4%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -7.6%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -79.1%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -33.8%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -96.7%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -23.1%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 99.3%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -13.0%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -75.8%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -13.0%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -20.2%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 20.0%Derived (calculated)
- Current ratio (FY 2025-12-31): 3.83xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 8.57xDerived (calculated)
- Return on equity (FY 2025-12-31): -466.6%Derived (calculated)
- Return on assets (FY 2025-12-31): -48.8%Derived (calculated)
- Net margin (FY 2025-12-31): -679.5%Derived (calculated)
- Total assets (annual): USD 293.24MSEC XBRL filing
- Total liabilities (annual): USD 262.59MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
- R&D expense (annual): USD 123.06MSEC XBRL filing
- Pre-tax income (annual): USD -142.76MSEC XBRL filing
- Cash & equivalents (annual): USD 65.8MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-17 00:00 UTCINSIDER19 insider transactions — 2026-06 · net sell $228k 7 derivative
2026-06-17INSIDERYaffe Kristine transacted 28.7k sh — Director
2026-06-17INSIDERLAVIGNE LOUIS J JR transacted 28.7k sh — Director
2026-06-17INSIDERDESOUZA ERROL B transacted 28.7k sh — Director
2026-06-17INSIDERAltmeyer Mark transacted 28.7k sh — Director
2026-06-17INSIDERGAROFALO ELIZABETH A. transacted 28.7k sh — Director
2026-06-17INSIDERHammond Paula transacted 28.7k sh — Director
2026-06-17INSIDERSCHELLER RICHARD H transacted 28.7k sh — Director
2026-06-17INSIDERDESOUZA ERROL B acquired 9.4k sh Stock Option (right to buy) — Director
2026-06-17INSIDERSCHELLER RICHARD H acquired 9.4k sh Stock Option (right to buy) — Director
2026-06-17INSIDERYaffe Kristine acquired 9.4k sh Stock Option (right to buy) — Director
2026-06-17INSIDERGAROFALO ELIZABETH A. acquired 9.4k sh Stock Option (right to buy) — Director
2026-06-17INSIDERHammond Paula acquired 9.4k sh Stock Option (right to buy) — Director
2026-06-17INSIDERLAVIGNE LOUIS J JR acquired 9.4k sh Stock Option (right to buy) — Director
2026-06-17INSIDERAltmeyer Mark acquired 9.4k sh Stock Option (right to buy) — Director
2026-06-03INSIDERWong-Sarad Grace sold 3.5k sh — Principal Accounting Officer ~$7k
2026-06-02INSIDERRosenthal Arnon sold 87.2k sh — Director, Chief Executive Officer ~$172k
2026-06-02INSIDERWong-Sarad Grace sold 5.7k sh — Principal Accounting Officer ~$11k
2026-06-02INSIDERBerkley Neil Lindsay sold 19.4k sh — CFO & Chief Business Officer ~$38k
2026-06-01INSIDERSCHELLER RICHARD H transacted 10.8k sh — Director
2026-04-16 00:00 UTCINSIDER1 insider transaction — 2026-04
2026-04-16INSIDERWong-Sarad Grace sold 1.8k sh — Principal Accounting Officer ~$5k
2026-03-15 00:00 UTCINSIDER7 insider transactions — 2026-03 · net sell $264k
2026-03-15INSIDERBerkley Neil Lindsay transacted 54.6k sh — CFO & Chief Business Officer
2026-03-13INSIDERRosenthal Arnon transacted 116.2k sh — Director, Chief Executive Officer
2026-03-10INSIDERWong-Sarad Grace sold 1.0k sh — Principal Accounting Officer ~$3k
2026-03-03INSIDERWong-Sarad Grace sold 3.4k sh — Principal Accounting Officer ~$7k
2026-03-02INSIDERRosenthal Arnon sold 81.9k sh — Director, Chief Executive Officer ~$174k
2026-03-02INSIDERWong-Sarad Grace sold 8.1k sh — Principal Accounting Officer ~$17k
2026-03-02INSIDERBerkley Neil Lindsay sold 29.6k sh — CFO & Chief Business Officer ~$63k
2026-02-26 00:00 UTCINSIDER1 insider transaction — 2026-02
Showing the 40 most recent of 52 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage